NASDAQ · VRAX
Virax Biolabs Group Limited financials
$2.23−3.65%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY26 Mar 31 | FY25 Mar 31 | FY24 Mar 31 | FY23 Mar 31 |
|---|---|---|---|---|
| Revenue | $12.4K | $6.3K | $156.4K | $8.6K |
| Gross profit | $7.7K | -$53.1K | $50.6K | -$1.4K |
| Gross margin | 61.9% | −838.2% | 32.3% | −15.9% |
| Operating income | -$6.4M | -$6.1M | -$6.4M | -$5.7M |
| Net income | -$5.0M | -$6.1M | -$6.7M | -$5.5M |
| Net margin | −40439.1% | −95739.2% | −4304.8% | −63748.3% |
| Diluted EPS | $-12.64 | $-40.62 | $-83.90 | $-128.25 |
| EBITDA | -$6.0M | -$5.8M | -$6.3M | -$5.7M |
| Operating cash flow | -$4.6M | -$4.6M | -$6.4M | -$4.2M |
| Free cash flow | -$4.9M | -$5.2M | -$7.3M | -$4.2M |
| Diluted shares | 0.4M | 0.1M | 0.1M | 0.0M |
Balance sheet
| Period end | Mar 31 | Mar 31 | Mar 31 | Mar 31 |
|---|---|---|---|---|
| Cash & equivalents | $6.4M | $4.2M | $3.6M | $9.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $28.5K | $32.5K | $0.00 | $0.00 |
| Total assets | $8.3M | $6.4M | $5.5M | $9.8M |
| Total liabilities | $989.8K | $964.8K | $345.2K | $908.4K |
| Shareholders' equity | $7.3M | $5.5M | $5.1M | $8.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology